APP and Alzheimer disease: Our findings demonstrate the efficacy of chronic administration of fullerene or fullerenol on AD-related outcomes in aged APP/PS1 female mice, underscoring the potential of fullerenol as a therapeutic agent for AD due to its superior ability to reduce amyloid plaque burden compared to fullerene.